ArticleDiscover oncology2026
Additive anti-tumor and immunomodulatory effects of Sporoderm-removed Ganoderma lucidum spore powder and anti-PD-L1 antibody in lung cancer mice.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anticancer Properties of Selected Wood-Inhabiting Fungi.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe therapeutic efficacy of programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors in lung cancer management remains suboptimal. Sporoderm-removed Ganoderma Lucidum Spore Powder (RGLS), an immunostimulant, has been shown to amplify the anti-tumor effects of anti-PD-L1 antibodies (αPD-L1). However, the detailed molecular underpinnings of this enhancement are not yet fully elucidated. This study aimed to elucidate the antitumor mechanism and immunomodulatory effect of RGLS in additive effect relationship with αPD-L1 in lung cancer.
methodsEmploying network pharmacology approaches, this research analyzed the multifaceted target pathways of RGLS in lung cancer. High-Performance Liquid Chromatography (HPLC) facilitated the identification of RGLS constituents. In the established Lewis lung cancer tumor-bearing mouse model, the effects of RGLS, αPD-L1, and their combination were investigated, focusing on tumor growth, T cell responses, and the dynamics of myeloid-derived suppressor cells (MDSCs) within tumor microenvironments.
resultsOur network analysis revealed 26 bioactive components of RGLS and identified 227 potential lung cancer targets, among which PD-L1 had a significant response effect with 20 core targets. HPLC identified 14 triterpenoid components. Notably, the combination of RGLS and αPD-L1 significantly inhibited tumor growth, optimized the CD4+/CD8+ T cell ratio in tumor tissue, increased IL-2 and IFN-γ levels, enhanced cytotoxic T lymphocyte (CTL) activity, and inhibited MDSCs recruitment.
conclusionThe additive effect application of RGLS and αPD-L1 in lung cancer treatment significantly improves immune responsiveness and reduces tumor-associated MDSCs, surpassing the efficacy of sole αPD-L1 application. This study underscores RGLS’s burgeoning potential in bolstering lung cancer immunotherapy, paving the way for its clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.